Compare Bath & Body Works Inc (BBWI) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Incyte Corporation — how do they compare? Bath & Body Works Inc trades at $19 (market cap $3.81B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 6.4× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 4.24% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BBWI | INCY | |
|---|---|---|
Market Cap | $3.81B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $129.93 |
52-Week Low | $14.85 | $81.61 |
Enterprise Value | $7.70B | $20.04B |
Dividend Yield | 4.24% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
